ERDRP-0519

ERDRP-0519

Systematic (IUPAC) name
2-methyl-N-[4-[(2S)-2-(2-morpholin-4-ylethyl)piperidin-1-yl]sulfonylphenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide
Clinical data
Legal status	Investigational New Drug
Identifiers
CAS Number	1374006-96-8
PubChem	CID 57521469
Chemical data
Formula	C23H30F3N5O4S
Molar mass	529.574
SMILES C4COCCN4CCC1CCCCN1S(=O)(=O)c(cc3)ccc3NC(=O)c2cc(C(F)(F)F)nn2C

ERDRP-0519 is an antiviral drug which is the first drug specifically developed to target the measles morbillivirus. It acts as an inhibitor of the viral enzyme RNA polymerase which is essential for viral replication, and in animal studies showed good oral bioavailability and protected ferrets from otherwise lethal doses of a morbillivirus when administered up to three days after infection.^[1][2]

See also

• Favipiravir
• JK-05
• Sofosbuvir

References

1. White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper RK (2007). "Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity". Antimicrobial Agents and Chemotherapy 51 (7): 2293–303. doi:10.1128/AAC.00289-07. PMC 1913224. PMID 17470652.
2. Krumm, S. A.; Yan, D.; Hovingh, E. S.; Evers, T. J.; Enkirch, T.; Reddy, G. P.; Sun, A.; Saindane, M. T.; Arrendale, R. F.; Painter, G.; Liotta, D. C.; Natchus, M. G.; von Messling, V.; Plemper, R. K. (2014). "An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model". Science Translational Medicine 6 (232): 232ra52. doi:10.1126/scitranslmed.3008517. PMID 24739760.